Q&A: Page 4
Exclusive interviews with industry leaders
-
Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm
The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.
Michael Gibney • Feb. 16, 2023 -
Managing for resilience: Passage’s ups and downs in gene therapy
After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.
Meagan Parrish • Feb. 15, 2023 -
Brian Fox is bringing ‘fresh eyes’ to ad agency Klick
Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.
Karissa Waddick • Feb. 13, 2023 -
Rocket Pharmaceuticals is ready for liftoff in the rare disease space
With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.
Taren Grom • Feb. 10, 2023 -
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.
Kelly Bilodeau • Feb. 6, 2023 -
Astria Therapeutics’ edge in an ultra-rare disease
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
Taren Grom • Feb. 1, 2023 -
This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic
With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.
Michael Gibney • Jan. 31, 2023 -
Gilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
Meagan Parrish • Jan. 26, 2023 -
Already on a roll in oncology, Astellas hunts for big wins in other areas
With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point.
Karissa Waddick • Jan. 23, 2023 -
UBC crowns Bekki Brown as its new CEO with a clear mandate to grow
The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.
Taren Grom • Jan. 20, 2023 -
A Moderna tie-up ushers in new era for CytomX
The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.
Michael Gibney • Jan. 18, 2023 -
Galecto has identified a master switch to reduce fibroid formation
With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.
Taren Grom • Jan. 11, 2023 -
Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck
The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.
Taren Grom • Jan. 9, 2023 -
To drive trial diversity, one company is bringing them to the patient
For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.
Karissa Waddick • Dec. 21, 2022 -
Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career
With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.
Taren Grom • Dec. 9, 2022 -
Takeda’s global quest for health equity
Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.
Taren Grom • Dec. 8, 2022 -
For Duchenne-focused Sarepta, gene therapy is the natural next step
The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.
Michael Gibney • Dec. 8, 2022 -
A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’
The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug.
Meagan Parrish • Dec. 6, 2022 -
Non-toxic and addiction free: The promise of a new pain med
Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.
Taren Grom • Dec. 1, 2022 -
Evommune’s unique method of drug discovery is more than skin deep
The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.
Michael Gibney • Nov. 29, 2022 -
In cancers with very low survival rates, Sellas aims higher
The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.
Kelly Bilodeau • Nov. 21, 2022 -
The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur
Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.
Taren Grom • Nov. 11, 2022 -
Novo Nordisk’s quantum bet on ‘world changing’ computing
Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.
Taren Grom • Nov. 10, 2022 -
The other ‘D’ in DE&I
How companies can work to include people with disabilities into broader equity aims.
Taren Grom • Nov. 4, 2022 -
Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that
The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.
Alexandra Pecci • Nov. 1, 2022